DCC-2036(Rebastinib)
编号: 52023
Cas号: 1020172-07-9
纯度: 98%
Rebastinib(DCC-2036;DCC2036) is an inhibitor of tyrosine kinases TIE2 and ABL1.Rebastinib(DCC2036) can prevent primary tumor growth and lung metastasis in the PyMT breast cancer model. Rebastinib is approximately 50 times more potent as an inhibitor of TIE2 than BCR-ABL.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | DCC-2036(Rebastinib) |
|---|---|
| Iupac 化学名称 | 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea |
| 同义词 | DCC-2036,Rebastinib;DCC2036;DCC 2036 |
| 英文同义词 | DCC-2036, Rebastinib, DCC2036, DCC 2036 |
| 分子式 | C30H28FN7O3 |
| 分子量 | 553.59 |
| Smile | C(C)(C)(C)C1=NN(C(=C1)NC(=O)NC1=C(C=C(C=C1)OC1=CC(=NC=C1)C(NC)=O)F)C=1C=C2C=CC=NC2=CC1 |
| InChiKey | WVXNSAVVKYZVOE-UHFFFAOYSA-N |
| InChi | InChI=1S/C30H28FN7O3/c1-30(2,3)26-17-27(38(37-26)19-7-9-23-18(14-19)6-5-12-33-23)36-29(40)35-24-10-8-20(15-22(24)31)41-21-11-13-34-25(16-21)28(39)32-4/h5-17H,1-4H3,(H,32,39)(H2,35,36,40) |
| Cas号 | 1020172-07-9 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | off-white solid |
|---|---|
| 纯度 | 98% |
| 存储 | 3 years -20ºCpowder 6 months-80ºCin solvent |
| 可溶性 | 5mg/ml in DMSO |
| 处理方式 | |
| 运输条件 | Shipped under ambient temperature |
| 海关编码 | 2933290090 |
| Targets | Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50 of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
Not available
_1020172-07-9.png)